MAP1LC3A and pulmonary fibrosis: On the other hand, Br-MSCs and/or saroglitazar treatment, that was initiated 14 days after pulmonary fibrosis induction, showed significantly (p < 0.05) increased protein levels of Beclin-1 (Table 2, Fig. 3) and expression levels of LC-3 and Beclin-1 (Table 4) when compared to BLM-G.